Product
*Actual vial appearance, contents, and dosage may vary and is based on your prescription.

GLP-1 Oral Drops

The GLP-1 Oral Drop offers powerful support in a convenient, needle-free dose, designed to help promote weight loss, reduce appetite, and support metabolic health. Just swish in your mouth, no injections, no refrigeration, and no daily routine, making it an effortless fit for your lifestyle. Powered by EllievaTec™, a proprietary Advanced Absorption Technology studied for over a decade, this advanced system is designed for effective delivery through the mouth, so you get more from every drop.

Free Shipping

Free Shipping

info-icon
Medical Consultation Included

Medical Consultation Included

info-icon

$299

Per Month

$897

Full Price

  • Available in all 50 states!
    • No Injections, No Daily Routine – Enjoy GLP-1 support in a simple oral drop, just swish and go!
    • No hidden membership, consultation, or shipping fees
    • A licensed healthcare practitioner in your state will review your assessment and determine your eligibility.

Testimonials

Read what our customers have to say about our products.

Scientific Sources

1. GLP-1 Science-Backed Support
Study: Once‑Weekly Semaglutide in Adults with Overweight or Obesity Wilding, J. P. H., et al. (2021).
Description: GLP‑1 receptor agonists have been shown in clinical trials to enable individuals to lose 15–17% of their body weight over approximately 68 weeks when paired with lifestyle modifications—ranking among the most effective approved weight-loss therapies.
Source:

New England Journal of Medicine, 384, 989–1002. doi:10.1056/NEJMoa2032183

PMC+15New England Journal of Medicine+15The Times+15ResearchGate

2. Appetite & Craving Control
Study: Effect of Oral Semaglutide 50 mg on Energy Intake, Appetite, and Control of Eating Gabe, M. B. N., et al. (2024).
Description: GLP‑1 therapy significantly reduces hunger, cravings, and total energy intake—participants on oral semaglutide lowered caloric intake by nearly 39% and reported greater fullness while consuming fewer high-fat foods.
Source:

Diabetes, Obesity and Metabolism, doi:10.1111/dom.15802

Wikipedia+13ResearchGate+13Applied Clinical Trials+13

3. Improved Blood Sugar Regulation
Study: Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Husain, M., et al. (2019).
Description: Oral semaglutide has demonstrated robust reductions in HbA1c and improved glycemic control in individuals with type 2 diabetes, supporting long-term metabolic management.
Source:

New England Journal of Medicine, 381, 841–851. doi:10.1056/NEJMoa1901118

Region Hovedstadens forskningsportal+15New England Journal of Medicine+15ClinicalTrials.gov+15


4. Cardiometabolic Support
Study: SELECT Trial – Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes Rubino, D., et al. (2023).
Description: Use of GLP‑1 therapies like semaglutide is associated with lower blood pressure, improved cholesterol profiles, reduced inflammation, and a reduced risk of major cardiovascular events.
Source:

Journal of the American College of Cardiology (SELECT trial)

PubMed+1Applied Clinical Trials+1


5. Off‑Label Uses Under Medical Supervision
Study: GLP‑1 therapies are being explored off-label for conditions such as PCOS, NAFLD, and obesity-related sleep apnea, with early studies indicating benefits in hormone regulation, liver fat reduction, insulin sensitivity, and weight-related inflammation.
Source:

GLP‑1 Receptor Agonists for Treatment of Nontraditional IndicationsTan, T. M., et al. (2023). Frontiers in Endocrinology, 14, 1163123. doi:10.3389/fendo.2023.1163123
PubMed+6PubMed+6Wiley Online Library+6

6. Advanced Absorption Technology (EllievaTec™ / ALM DT)
Study: The ALM DT delivery system (licensed as EllievaTec™) was used in a dissolving oral granule formula designed for sublingual absorption and body recomposition, demonstrating effective uptake through the mucosal membrane and providing a needle-free alternative to traditional delivery methods.
Source:

Effective Body Recomposition vs. Misconceptions of Traditional Weight Loss Strategies: TRCAP21
Morrison, B. S., & Hesson, S. (2022). Functional Foods in Health and Disease, 12(4), 134–150. doi:10.31989/ffhd.v12i3.905

Study: The ALM DT delivery system (licensed as EllievaTec™) was also utilized in a swish-and-swallow oral formula combining bioflavonoids and electrolytes, which demonstrated enhanced absorption and performance support in athletes.
Source:

Design of a Novel Bioflavonoid and Phytonutrient Enriched FormulationDowns, B. W., et al. (2021). American Journal of Biopharmaceutics and Pharmaceutical Sciences, 1(2). doi:10.25259/AJBPS_2_2021

Study: A sublingual multi-enzyme formula utilizing the ALM DT delivery system (licensed as EllievaTec™) showed promising absorption results and was evaluated for safety and efficacy in a randomized, double-blind, placebo-controlled human trial.
Source:

Safety and Efficacy of N-SORB®: A Proprietary Metabolically Activated Enzyme FormulationBagchi, M., et al. (2019). Journal of the American College of Nutrition. doi:10.1080/07315724.2019.1704467

Frequently Asked Questions

Expand the questions below

Get the latest updates and exclusive offers by subscribing to our newsletter.

By subscribing, you agree to our Privacy Policy and consent to receive updates.